Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
annexin v Recently several dual GLP GIP receptor agonists
2021-10-18

Recently, several dual GLP-1/GIP receptor agonists have been developed as a treatment of type II diabetes. These peptides can activate both the GLP-1 and the GIP receptor. Such dual receptor agonists are superior compared to single GLP-1 analogues such as liraglutide (Finan et al., 2013). Previously
-
br Presenilins and Wnt catenin signalling Several
2021-10-18

Presenilins and Wnt/β-catenin signalling Several groups have provided substantial data indicating that PS1 acts as a negative modulator of the transcriptional activity of the β-catenin/Tcf-4 complex (Fig. 4) [120], [121], [122]. β-Catenin is a multifunctional protein that was first described as
-
br Materials and methods br Results To examine the apoptosis
2021-10-16

Materials and methods Results To examine the apoptosis in FLS in vitro, we measured the number of Bupivacaine HCl in early apoptosis (Annexin V+, 7-AAD−) and late apoptosis/necrosis (Annexin V+, 7-AAD+) using flow cytometry after incubation with or without stimulating Fas antibody. In the abs
-
br Materials and methods Patients charts
2021-10-16

Materials and methods Patients’ charts were reviewed retrospectively, and 165 consecutive patients (82 with cancer and 83 without cancer) who either started edoxaban (Lixiana®, Daiichi-Sankyo, Tokyo, Japan) therapy for the treatment of VTE or were switched from other oral anticoagulants to edoxab
-
br Acknowledgments br Introduction Liver disease is one of
2021-10-16

Acknowledgments Introduction Liver disease is one of the leading causes of death worldwide. Death from any type of acute or chronic liver injury results when sufficient healthy hepatic parenchyma cannot be regenerated to perform vital liver-specific functions. Although the regenerative capabil
-
Compound a substituted phenyl H pyrano d d dipyrimidine
2021-10-16

Compound 6, a 5-(4-substituted-phenyl)-5H-pyrano[2,3-d:-6,5-d′]dipyrimidine derivative was invented previously to have significant efficacy to inhibit HIV integrase enzyme with 0.9 ± 0.4 μM of IC50 against 3′-processing and 16.1 ± 10.7 μM of IC50 against strand transfer suppression. The compound ind
-
Several compounds have been described in the literature as i
2021-10-16

Several compounds have been described in the literature as inhibitors of the sGC. Among them, methylene blue and LY83583 () are not direct sGC inhibitors, but rather block cGMP formation by generating superoxide anion radicals that deactivate NO. Despite their extensive use in plethora of research s
-
br Introduction Coat colors are determined by both genetics
2021-10-16

Introduction Coat colors are determined by both genetics and environment, especially genetics. The phenotype of coat color of animals depends on two types of melanin, black to brown eumelanin and yellow to reddish brown pheomelanin produced in mammalian melanocyte (Ito et al., 2000; Ito and Wakam
-
dna staining One important aspect about GSK inhibitors
2021-10-16

One important aspect about GSK-3 inhibitors is their effect on pluripotency of dna staining [4]. Many GSK-3 inhibitors are ATP-competitive and suppress both GSK-3alpha and GSK-3beta [476]. BIO was shown to suppress GSK-3 activity and promote Wnt/beta-catenin signaling. This combination of events pre
-
br Lactate metabolism L Lactate is
2021-10-16

Lactate metabolism L-Lactate is an intermediate metabolite in glucose metabolism. Glucose can be broken down to pyruvate, and pyruvate can be either further oxidized to acetyl-CoA and enter the TCA cycle, or reduced to L-lactate by lactate dehydrogenase (LDH). In turn, LDH can oxidize L-lactate t
-
br MUTYH associated polyposis br MUTYH
2021-10-16

MUTYH-associated polyposis MUTYH and its metal cofactors MUTYH harbors two vital cofactors, both of which are located remotely from the active site (Fig. 6). One of these cofactors, a [4Fe-4S]2+(Fe-S) cluster, is chelated by four Cys residues in the N-terminal domain, and positions an Fe-S cl
-
In our study we observed elevation of the fluorescent
2021-10-16

In our study, we observed elevation of the fluorescent intensity in the layers without synaptic contacts (OS, ONL, INL, and GCL). In the enzyme-linked fluorescence assay system, released glutamate is catalyzed by the enzyme on the surface of a quartz glass. Therefore, the diffusion of glutamate onto
-
The transport of glutamate by EAAT from the extracellular
2021-10-16

The transport of glutamate by EAAT2 from the extracellular fluid into either astrocytes or endothelial cells is an unfavorable and energy-consuming process. This energy is provided by a coupled co-transport of three sodium ions, one proton, and one glutamate molecule in the counter-transport of one
-
Here we investigated on epigenetic regulatory
2021-10-15

Here, we investigated on epigenetic regulatory mechanisms of ALX/FPR2 expression. Epigenetic changes, that include phosphorylation, acetylation, methylation and ubiquitination of DNA and histone proteins, occur in a variety of diseases [21] and are being recognized as key targets for personalized me
-
Hyperhomocysteinemia HHcy is a clinical condition characteri
2021-10-15

Hyperhomocysteinemia (HHcy) is a clinical condition characterized by increased levels of plasma homocysteine (Hcy) and a well-known risk factor for CVDs. Hcy is a sulfur-containing non-protein amino debio formed during the intracellular conversion of methionine to cysteine. Previous study demonstra
16177 records 598/1079 page Previous Next First page 上5页 596597598599600 下5页 Last page